Gamma-hydroxybutyrate in the treatment of schizophrenia.
Gamma-Hydroxybutyrate (GHB) inhibits firing of dopaminergic neurons and is thus potentially useful in the treatment of schizophrenia. GHB was administered to 10 schizophrenics concurrently with low-dose fluphenazine in a 6-week double-blind crossover study. No antipsychotic efficacy of GHB was noted. GHB had little if any effect on plasma prolactin levels after a single administration and caused few side effects. Trials with higher doses of GHB may be warranted.
D000328:Adult; D004311:Double-Blind Method; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006885:Hydroxybutyrates / Q000627:therapeutic use*; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D012565:Schizophrenic Psychology; D012978:Sodium Oxybate / Q000627:therapeutic use*
D006885:Hydroxybutyrates; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D012978:Sodium Oxybate; D011388:Prolactin; D006719:Homovanillic Acid